-
Ruxolitinib
Ingoa API Tohutohu Kaihanga hou Te Ra Whakamutunga Patent(Te US) Ruxolitinib Myelofibrosis Novartis Hurae 6, 2024 -
Crisaborole
Ingoa API Tohutohu Kaihanga hou Te Ra Whakamutunga Patent(Te US) Crisaborole Dermatitis Atopic me te Eczema Pfizer Hune 11, 2026 -
Relugolix
Ingoa API Tohutohu Kaihanga hou Te Ra Whakamutunga Patent(Te US) Relugolix mate pukupuku Prostatic Takeda me ASKA Hanuere 24, 2024 -
Vericiguat
Ingoa API Tohutohu Kaihanga hou Te Ra Whakamutunga Patent(Te US) Vericiguat Te ngoikore o te ngakau Bayer me MSD Mei.24, 2031 -
Abrocitinib
Ingoa API Tohutohu Kaihanga hou Te Ra Whakamutunga Patent(Te US) Abrocitinib Dermatitis Atopic Pfizer Feb.11, 2034 -
Rimegepant
Ingoa API Tohutohu Kaihanga hou Te Ra Whakamutunga Patent(Te US) Rimegepant Migraine ānini Biohaven Pepuere 22, 2031 -
Elagolix 834153-87-6
Ingoa API Tohutohu Whakatakotoranga US DMF EU DMF CEP ElagolixCAS:834153-87-6 Endometriosis Roto-whare -
Relugolix 737789-87-6
Ingoa API Tohutohu Whakatakotoranga US DMF EU DMF CEP Ribociclib CAS: 737789-87-6 Atineoplastic Roto-whare -
Venetoclax 1257044-40-8
Ingoa API Tohutohu Kaihanga hou Te Ra Whakamutunga Patent(Te US) Venetoclax 1257044-40-8 CLL Abbvie Hune.27,2031 -
Velpatasvir(PVP)
Ingoa API Tohutohu Whakatakotoranga US DMF EU DMF CEP Velpatasvir(PVP) HCV Roto-whare √ -
Ko te Thalidomide
Ingoa API Tohutohu Whakatakotoranga US DMF EU DMF CEP Ko te Thalidomide Te rongoa oncology USP/EP -
Ticagrelor
Ingoa API Tohutohu Whakatakotoranga US DMF EU DMF CEP Ticagrelor Te whakakorikori Roto-whare 28984 √